Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3603537 | 0.99 | ADRB1 (0.47) | ADRB1ALDH1A1ALOX5KMT2AHSD11B1 | |
| Hydrochloric Acid SCHEMBL3599255 | 0.85 | HTR2C (0.40) | ALDH1A1ALOX5 | |
| Hydrochloric Acid SCHEMBL3604632 | 0.85 | DDB1 (0.44) | ADRB1 | |
| Hydrochloric Acid SCHEMBL3605372 | 0.85 | HTR2C (0.48) | ADRB1ALDH1A1ALOX5KMT2A | |
| SCHEMBL3601347 | 0.84 | ALOX5 (0.43) | ALOX5 | |
| Hydrochloric Acid SCHEMBL3604157 | 0.84 | ADRB1 (0.49) | ADRB1ALDH1A1ALOX5KMT2A | |
| Hydrochloric Acid SCHEMBL3601870 | 0.84 | ATM (0.41) | ALDH1A1ALOX5KMT2AHSD11B1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3600853 | 0.84 | OPRM1 (0.41) | ALDH1A1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3611639 | 0.83 | ALOX5 (0.44) | ALDH1A1ALOX5 | |
| Hydrochloric Acid SCHEMBL3599890 | 0.83 | GRM2 (0.40) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | ADRB1 224/4885ALDH1A1 1162/4885ALOX5 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.